SFM
SAGE

Sphera Funds Management’s Sage Therapeutics SAGE Stock Holding History

Sphera Funds Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-24,500
Closed -$2.35M – 117
2018
Q4 		$2.35M Buy
+24,500
New +$2.8M 0.26% 69
2018
Q1 		– Sell
-2,400
Closed -$395K – 137
2017
Q4 		$395K Hold
2,400
– – 0.05% 123
2017
Q3 		$150K Buy
+2,400
New +$188K 0.02% 127

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sphera Funds Management's SAGE Position: Q3 2023 in Review

Sphera Funds Management sold out of Sage Therapeutics (SAGE) in Q3 2023, closing a stake of 128,000 shares — an estimated $6.02M sold.

Sphera Funds Management first reported a position in SAGE in Q3 2014 and held it in 19 quarters. The position peaked at $9.91M in Q4 2018. 194 funds tracked by Wall St. Rank hold SAGE as of Q3 2023.

  • Sphera Funds Management reported no remaining Sage Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Sphera Funds Management sold 128,000 Sage Therapeutics shares in Q3 2023, an estimated $6.02M.
  • Sphera Funds Management first reported a position in Sage Therapeutics in Q3 2014 and held it in 19 quarters.
  • Sphera Funds Management's Sage Therapeutics position peaked at $9.91M in Q4 2018.
  • 194 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2023.

Based on Sphera Funds Management's 13F filing for Q3 2023, filed 14 Nov 2023.